Dermatology

A new systematic review has shed light on the safety of beta blockers for treating PHACE syndrome, addressing concerns about stroke risk in patients with cerebrovascular and cardiovascular anomalies.

A recent study has highlighted metformin’s potential role in reducing the risk of non-melanoma skin cancers (NMSC), offering intriguing possibilities for dermatological and oncological care.

A new study reveals that patients with cutaneous lupus erythematosus (CLE) face significantly higher risks of atherosclerotic cardiovascular disease (ASCVD) compared to the general population.

A recent study has uncovered promising advancements in the fight against Stage II melanoma by introducing a novel biomarker technique, immune Förster resonance energy transfer (iFRET).

An epidemiological study has shed light on the primary risk factors driving Merkel cell carcinoma (MCC), a rare but aggressive form of skin cancer.

Patients with moderate-to-severe atopic dermatitis who did not initially meet response criteria for lebrikizumab at 16 weeks can still achieve improvements with continued therapy, according to a recent clinical trial analysis.

The VISIBLE trial sets a benchmark for diversity in psoriasis research, achieving rapid enrollment and valuable data for patients with skin of color.

The most commonly treated pediatric cosmetic conditions included hypertrophic and traumatic scars, acne, axillary and facial hyperhidrosis.